319 related articles for article (PubMed ID: 32294155)
1. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.
Magisetty J; Kondreddy V; Keshava S; Das K; Esmon CT; Pendurthi UR; Rao LVM
Blood; 2022 May; 139(18):2830-2841. PubMed ID: 35143636
[TBL] [Abstract][Full Text] [Related]
3. Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.
Keshava S; Sundaram J; Rajulapati A; Esmon C; Pendurthi U; Rao LVM
Blood Adv; 2017 Jun; 1(15):1206-1214. PubMed ID: 28932824
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis.
Rodríguez-Merchán EC
Clin Orthop Relat Res; 1997 Oct; (343):6-11. PubMed ID: 9345198
[TBL] [Abstract][Full Text] [Related]
5. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.
Ovlisen K; Kristensen AT; Valentino LA; Hakobyan N; Ingerslev J; Tranholm M
J Thromb Haemost; 2008 Jun; 6(6):969-75. PubMed ID: 18363814
[TBL] [Abstract][Full Text] [Related]
6. Factor VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in vivo.
Sundaram J; Keshava S; Gopalakrishnan R; Esmon CT; Pendurthi UR; Rao LV
J Thromb Haemost; 2014 May; 12(5):690-700. PubMed ID: 24977291
[TBL] [Abstract][Full Text] [Related]
7. A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo.
van Vulpen LFD; Popov-Celeketic J; van Meegeren MER; Coeleveld K; van Laar JM; Hack CE; Schutgens REG; Mastbergen SC; Lafeber FPJG
J Thromb Haemost; 2017 Sep; 15(9):1788-1798. PubMed ID: 28696534
[TBL] [Abstract][Full Text] [Related]
8. [Conservative management of hemophilic arthropathy].
Müller S; Kurth AA; Hovy L
Orthopade; 1999 Apr; 28(4):347-55. PubMed ID: 10335529
[TBL] [Abstract][Full Text] [Related]
9. Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice.
Nieuwenhuizen L; Roosendaal G; Mastbergen SC; Coeleveld K; Biesma DH; Lafeber FP; Schutgens RE
J Thromb Haemost; 2014 Feb; 12(2):237-45. PubMed ID: 24283895
[TBL] [Abstract][Full Text] [Related]
10. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
Sun J; Hakobyan N; Valentino LA; Feldman BL; Samulski RJ; Monahan PE
Blood; 2008 Dec; 112(12):4532-41. PubMed ID: 18716130
[TBL] [Abstract][Full Text] [Related]
11. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
Wyseure T; Yang T; Zhou JY; Cooke EJ; Wanko B; Olmer M; Agashe R; Morodomi Y; Behrendt N; Lotz M; Morser J; von Drygalski A; Mosnier LO
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465300
[TBL] [Abstract][Full Text] [Related]
12. The F8(-/-) rat as a model of hemophilic arthropathy.
Sørensen KR; Roepstorff K; Wiinberg B; Hansen AK; Tranholm M; Nielsen LN; Kjelgaard-Hansen M
J Thromb Haemost; 2016 Jun; 14(6):1216-25. PubMed ID: 27060449
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.
Cooke EJ; Wyseure T; Zhou JY; Gopal S; Nasamran CA; Fisch KM; Manon-Jensen T; Karsdal MA; Mosnier LO; von Drygalski A
J Thromb Haemost; 2019 Nov; 17(11):1815-1826. PubMed ID: 31301687
[TBL] [Abstract][Full Text] [Related]
14. IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia.
Narkbunnam N; Sun J; Hu G; Lin FC; Bateman TA; Mihara M; Monahan PE
J Thromb Haemost; 2013 May; 11(5):881-93. PubMed ID: 23413986
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
Keshava S; Pendurthi UR; Esmon CT; Rao LVM
J Thromb Haemost; 2020 Aug; 18(8):1911-1921. PubMed ID: 32359012
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
17. Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway.
Haxaire C; Hakobyan N; Pannellini T; Carballo C; McIlwain D; Mak TW; Rodeo S; Acharya S; Li D; Szymonifka J; Song X; Monette S; Srivastava A; Salmon JE; Blobel CP
Blood; 2018 Sep; 132(10):1064-1074. PubMed ID: 29776906
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
[TBL] [Abstract][Full Text] [Related]
19. Prevention of haemarthrosis in a murine model of acute joint bleeding.
Valentino LA; Hakobyan N; Kazarian T; Sorensen BB; Tranholm M
Haemophilia; 2009 Jan; 15(1):314-9. PubMed ID: 19149856
[TBL] [Abstract][Full Text] [Related]
20. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.
Wyseure T; Cooke EJ; Declerck PJ; Behrendt N; Meijers JCM; von Drygalski A; Mosnier LO
Blood; 2018 Oct; 132(15):1593-1603. PubMed ID: 30026184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
